|Assessment Status||Assessment process complete|
|Drug||Fluocinolone acetonide intravitreal implant|
|Indication||For the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.|
|Rapid review commissioned||23/11/2020|
|Rapid review completed||21/12/2020|
|Rapid review outcome||A full HTA is not recommended. The NCPE recommends that fluocinolone acetonide intravitreal implant not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations September 2022.